secwatch.observer — SEC 8-K summary
======================================

Issuer:     Claritev Corp (CTEV)
CIK:        0001793229
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001793229-23-000119
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MultiPlan Q3 2023 revenue $242.8M, net loss $24.1M; FY guidance tightened
-------------------------------------------------------------------------

- Q3 2023 revenue $242.8M (-3.1% YoY); net loss $24.1M vs net income $19.7M in Q3 2022.
- Adjusted EBITDA $152.3M; Free Cash Flow $49.7M, down from $88.2M prior year.
- Repurchased $46.1M face value of 5.75% Senior Unsecured Notes in open market during Q3.
- FY 2023 guidance updated: revenue $960-970M (from $950-980M), Adjusted EBITDA $615-625M (from $615-635M).
- Identified ~$5.8B in potential medical cost savings in Q3, up 7% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/0001793229-23-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1793229/000179322923000119/mpln-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001793229-23-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer